+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study



Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study



Transplantation 59(1): 45-50



Eighty-six consecutive liver transplant recipients were prospectively randomized in a double-blind, placebo-controlled antifungal prophylaxis study. Seventy-seven patients received 5 days of prophylaxis starting during the transplantation with either liposomal amphotericin B (AmBisome) 1 mg/kg/day or placebo. Among 40 AmBisome-treated patients, no invasive Candida infection was seen during the first month, compared with 5 invasive Candida albicans infections among 37 control patients (P < 0.05). Furthermore, 1 placebo patient experienced Aspergillus niger pneumonia. Thus, the overall incidence of invasive fungal infections was 0/40 (0%) in the AmBisome group versus 6/37 (16%) in the placebo group (P < 0.01). Patient survival at 30 days was 92% versus 94% for AmBisome- and placebo-treated patients, respectively. One patient experienced backache related to AmBisome infusion. Two patients had transient thrombocytopenia possibly caused by AmBisome treatment. AmBisome was otherwise well tolerated. The total cost for all antifungal drugs used in both groups was equal. However, prophylaxis with AmBisome was $5000 less expensive than treatment of proven invasive fungal infections among placebo patients.

(PDF emailed within 1 workday: $29.90)

Accession: 008961389

Download citation: RISBibTeXText

PMID: 7839427


Related references

Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long term results of a randomized, placebo-controlled trial. Transplantation Proceedings 27(1): 1195-1198, 1995

Liposomal Amphotericin B Prevents Invasive Fungal Infections In Liver Transplant Recipients. Transplantation 59(1): 45-50, 1995

Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplantation 12(6): 577-582, 1993

Prophylactic use of liposomal amphotericin B against fungal infections A randomized trial in bone marrow transplant recipients. Transplantation Proceedings 25(1 BOOK 1-2): 1495-1497, 1993

Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplantation Proceedings 25(1 Pt 2): 1495-1497, 1993

Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplantation Proceedings 37(9): 3965-3967, 2006

Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 315, 2002

Preemptive prophylaxis with lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring dialysis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 381, 2000

Invasive aspergillosis in liver transplant recipients in 1990s; risk factors and outcome with amphotericin B vs liposomal amphotericin B therapy. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 322, 1997

Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. Transplantation 96(6): 573-578, 2013

Treatment of fungal infections in heart transplant recipients using liposomal encapsulated amphotericin b. Journal of Heart Transplantation 7(1): 81, 1988

Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. Journal of Antimicrobial ChemoTherapy 52(5): 813-819, 2003

Preemptive Prophylaxis With A Lipid Preparation Of Amphotericin B For Invasive Fungal Infections In Liver Transplant Recipients Requiring Renal Replacement Therapy1. Transplantation 71(7): 910-913, 2001

Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 71(7): 910-913, 2001

Antifungal prophylaxis in bone marrow transplant recipients Results of a double-blind randomized study of liposomal amphotericin B vs placebo. Journal of Cellular Biochemistry Supplement 0(18B): 62, 1994